Sitemap
Expertise
- Competition and FDI
- Data privacy
- ECM - IPOs and secondary financings
- Employment, pensions and incentives advice
- Healthcare
- HealthTech and Techbio
- Intellectual property
- Investments and financings
- Licensing and collaboration agreements
- M&A
- Manufacturing & Tech Ops
- Multi-jurisdictional disputes
- Public procurement
- Real estate for laboratory and manufacturing facilities
- Regulatory and investigations
- Tax structuring
Insight
- Biotech listings in Hong Kong
- A view from the practitioners: AIM at 25 podcast
- AI update – the regulatory approach to AI and medical products in the UK
- Antitrust: Impact of COVID-19 on life sciences
- Changes to the Listing Rules - SPACs
- Changes to UK R&D SME tax credits
- Court orders damages and civil penalties for unlawful NHS procurement
- COVID-19 considerations for life sciences M&A
- COVID-19 vaccine patent waivers
- Cybersecurity in the life sciences industry: Fail to prepare; prepare to fail
- D-day announced – UK's new National Security and Investment Act regime to begin on 4 January 2022
- Documents disclosed to the EMA as part of an MA application process are not presumed to be confidential
- EMI employee share options and acceptable discretion
- How to practise safe working in labs and research facilities
- Impact of Covid-19 on market abuse risks on businesses in the life sciences sector
- Life sciences - Still in the antitrust spotlight
- Life sciences A to Z - A is for Artificial Intelligence
- Life sciences A to Z - B is for Biologics License Application
- Life sciences A to Z - C is for collaboration arrangements
- Life sciences A to Z - D is for data opt-out
- Life sciences A to Z - E is for equity investment
- Life sciences A to Z - F is for foreign investment: UK’s new foreign investment screening regime – What you need to know?
- Life sciences A to Z - G is for gene-editing: The CRISPR landscape
- Life sciences A to Z - H is for hungry capital companies - life sciences businesses and the new Pre-Emption Group Principles
- Life sciences A to Z - I is for investment allocation
- Life sciences A to Z - J is for jumping the gun
- Life sciences A to Z - JK is for JPM: what to Know
- Life sciences A to Z – L is for Leasing in life sciences
- Life sciences A to Z – M is for Manufacturing: Is insourcing the new outsourcing?
- Life sciences podcast
- Public procurement in the life sciences sector post Brexit – what you need to know
- Take two: What's new in the Latest UK Data Protection and Digital Information Bill?
- The Public Procurement Bill 2022 has a second reading in the House of Lords
- Time to reap the benefits? The UK's new subsidy control regime comes into effect
- UK government blocks IP licence over national security concerns
- UK Government provides more clarity on the scope of the National Security and Investment Bill (“NSIB”)
- UK Public Procurement Reform in the life sciences sector – What's the latest?
- Under the antitrust spotlight: patent litigation
- What the life sciences sector needs to know about supplying to the UK public health service post Brexit
News
- Kristian Shearsby joins Stephenson Harwood as partner
- Partner Alexandra Pygall joins Babraham Institute Board
- Stephenson Harwood advises Acacia Pharma on €27 million fundraise
- Stephenson Harwood advises Apposite Capital on Emblation investment
- Stephenson Harwood advises BenevolentAI on strategic collaboration with Merck
- Stephenson Harwood advises Bicycle Therapeutics on radiopharmaceuticals deal with Novartis
- Stephenson Harwood advises Bicycle Therapeutics on radiotherapy deal with Bayer
- Stephenson Harwood advises capiton on KD Pharma single-asset secondary
- Stephenson Harwood advises Dr. Falk on acquisition of Kynos Therapeutics
- Stephenson Harwood advises e-therapeutics plc on £22.5 million fundraise
- Stephenson Harwood advises Flarin on fundraise
- Stephenson Harwood advises GE Healthcare on transformative Zionexa acquisition
- Stephenson Harwood advises Hong Kong AI business on reverse merger and NASDAQ listing
- Stephenson Harwood advises Lansen Pharmaceutical on privatisation
- Stephenson Harwood advises Novacyt on Yourgene Health takeover
- Stephenson Harwood advises on $25 million funding in ViaNautis Bio
- Stephenson Harwood advises on healthcare data acquisition
- Stephenson Harwood advises Oxford Biomedica on COVID-19 vaccine with AstraZeneca
- Stephenson Harwood advises Oxford Biomedica on gene therapy collaboration
- Stephenson Harwood advises Oxford Biomedica on new AstraZeneca agreement
- Stephenson Harwood advises Schroder UK Public Private Trust on £49 million asset sale
Team
- Alexandra Pygall
- Catriona Berman
- Guillaume Briant
- Archie Campbell
- Rebecca Carter
- Anthony Clare
- Nicolas Demigneux
- Marta Isabel Garcia
- Michelle Gomes
- Dan Holland
- Karima Hudson
- Rob Jacob
- Sean Jeffrey
- Danny Kan
- Naomi Leach
- Justin McClelland
- Jane Ng
- Tom Page
- Anne Pritam
- Kristian Shearsby
- Dan Smith
- Nicholas Stretch
- Amy Yu
- Trudy Feaster-Gee
- Alison Llewellyn
- Kate Ackland
- Bobbie Bickerton
- Sriya Coomer
- Seth Crawley
- Alice Routh
- Ainsleigh Stone